Logo

VolitionRx Closes Public Offering, Raises $8.5M

Feb 12, 2015 | staff reporter

NEW YORK (GenomeWeb) – VolitionRx today announced it has closed its public offering of 2,475,000 shares of stock at an offering price of $3.75 per share for net proceeds of about $8.5 million.

The firm's stock began trading on the New York Stock Exchange MKT on Feb. 6, under the ticker symbol "VNRX."

The firm said it intends to use the proceeds to fund prospective colorectal trials with Hvidovre Hospital in Denmark and an ongoing study at University Hospital in Bonn, Germany, as well as for general working capital.

National Securities, a wholly owned subsidiary of National Holdings, and Lake Street Capital Markets acted as joint book-running managers for the offering. The Benchmark Company acted as co-manager for the offering.

Filed under

Cancer
Business News
Molecular Diagnostics
stock offering
Colorectal Cancer
VolitionRx
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.